EML4 and cancer: Similarly, a significant reduction in cell viability was observed in an A3B-knockout (KO) EML4-ALK cancer cell line (H3122; Extended Data Fig. 4e,f) treated with the Food and Drug Administration-approved ALK TKI alectinib (Fig. 3n).